Press Releases Tenaya Therapeutics, Inc.

Stocks

TNYA

US87990A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:32:21 2026-07-13 pm EDT			5-day change	1st Jan Change
0.8090 ^USD	-7.05%		-7.56%	+12.44%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Press Releases

Jun. 29	Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer	AQ
Jun. 03	Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms	AQ
Jun. 02	Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026	AQ
May. 29	Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026	AQ
May. 15	Tenaya Therapeutics : Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 in Adults with PKP2-associated ARVC Presented at ASGCT 2026 Presentation (d2e3d8)	PU
May. 15	Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC	AQ
May. 06	Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
Apr. 27	Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026	AQ
Mar. 11	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
Mar. 09	Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy	AQ
Mar. 02	Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026	AQ
Jan. 09	Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones	AQ
Dec. 12	Tenaya Therapeutics : Interim Data from RIDGE-1 Phase 1b Clinical Trial of TN-401 in Adults with PKP2-associated ARVC Presentation (3cfa6f)	PU
Dec. 12	Tenaya Therapeutics Announces Pricing of Public Offering	AQ
Dec. 11	Tenaya Therapeutics : Interim Data from RIDGE-1 Phase 1b Presentation (0d243d)	PU
Dec. 11	Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC	AQ
Dec. 11	Tenaya Therapeutics Announces Proposed Public Offering	AQ
Dec. 11	Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy	AQ
Nov. 10	Tenaya Therapeutics : Interim Clinical Data from MyPEAK-1 Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated HCM Presentation (5ce410)	PU
Nov. 10	Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
Nov. 08	Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy	AQ
Nov. 04	Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025	AQ
25-10-09	Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference	AQ
25-10-02	Tenaya Therapeutics to Participate in Upcoming October Investor Conferences	AQ
25-09-18	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ